Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “Investors”) for the sale of 10,127,132 of its ordinary shares, for an approximate value of USD 166 million, par value USD 0.01 per share (the “Shares”), at a purchase price of USD 16.41 per Share, or ISK 2,250 per share at foreign exchange rates on February 23, 2024 (the “Transaction”). The Shares are expected to be delivered to investerarna från tidigare emitterade egna aktier som innehas av Alvotechs dotterbolag, Alvotech Manco ehf. Transaktionen kommer att göras på Nasdaq Islands börs.
Alvotech accepterar bud om försäljning av aktier till ett värde av cirka 166 miljoner USD till ett köpeskilling på 16.41 USD (2,250 XNUMX ISK) per aktie
